LARALAB

Company profile

About LARALAB

LARALAB, now part of Abbott, has developed heart.ai, the first fully automated cloud-based solution for cardiac interventions and structural heart care. The platform is powered by deep learning AI to provide precise, data-driven insights for procedure planning in cardiovascular interventions and surgery. Heart.ai offers tailored workflows and clinical applications for structural heart interventions including tricuspid valve replacement (TTVR), transcatheter aortic valve replacement (TAVR), and transcatheter mitral valve replacement (TMVR). The platform features the REC (Rapid Eligibility Check) for pre-screening, a 4D DICOM viewer and analysis toolbox, and automated reporting capabilities that transform image data into clinical reports. LARALAB enables healthcare partners to build their own research registries and has been validated in over 20 clinical publications involving more than 1,000 patient datasets. The company serves health systems, cardiac intervention centers, and research institutions focused on structural heart disease. With both FDA 510(k) clearance and CE marking under MDR, the platform supports clinicians in making optimal treatment decisions for patients considered for cardiovascular interventions. LARALAB partners with leading medical institutions on registry studies including TTVR-AHI Registry, CESAR-TR, and MitrAI, advancing the field of AI-assisted cardiac care.

Company description · LARALAB official website